Risk factor
Very poor trading liquidity
Profitability factor
Slightly undervalued vs peers
About
Haleos Labs Limited, an Indian-based pharmaceutical enterprise, specializes in the production of crucial active pharmaceutical ingredients (APIs) and intermediate compounds. Their extensive portfolio encompasses a wide array of therapeutic applications, providing treatments for conditions such as ulcers, migraines, hypertension, and erectile dysfunction. Additionally, the company develops products for cancer, fungal infections, obesity, nausea, depression, parasitic infestations, various infectious diseases, gout, convulsions, viral ailments, and anesthesia. They also supply ingredients for antihistamines, diuretics, hair loss treatments, and ophthalmic preparations. A significant portion of their manufactured goods is destined for international markets. Established in 1990 and headquartered in Hyderabad, India, the firm was formerly known as SMS Lifesciences India Limited and is scheduled to officially adopt its current name, Haleos Labs Limited, in August 2025.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on EV/EBITDA, tradin